polycystic ovary syndrome
Conditions
Interventions
Test group:Transabdominal focused ultrasound irradiation of ovarian medulla
Sponsors
Foshan First People's Hospital
Eligibility
Sex/Gender
Female
Age
23 Years to 40 Years
Inclusion criteria
Inclusion criteria: (1) Women aged 23-40 years old; (2) Meets the diagnostic criteria for polycystic ovary syndrome: The diagnostic criteria for polycystic ovary syndrome jointly developed by the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) at the 2003 Rotterdam Conference are as follows: 1. anovulation or infrequent ovulation; 2. Clinical manifestations of hyperandrogenism and/or hyperandrogenism; 3. Ultrasound table indicates polycystic ovary syndrome (having 12 or more follicles with a diameter less than 10mm in one or both ovaries, and/or a volume greater than 10ml in one ovary); The above three conditions meet two of them; (3) Patients with refractory ovulation disorders: those who have fertility requirements, undergo routine ovulation induction, and use stepwise medication up to 50-100-150 mg qd * 5d of clomiphene citrate, 2.5-5-7.5 mg qd * 5d of letrozole, or 75-150-225 u qd * 7d of urinary gonadotropin, but still do not have follicle development; (4) Those who are willing to accept the experimental measures and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Medications that affect steroid hormone secretion (such as clomiphene citrate, letrozole, and gonadotropins) or ovulation (such as steroids, sedatives, antidepressants, and antiepileptic drugs) have been taken within one month; (2) Tumors that secrete androgens, congenital adrenal hyperplasia, Cushing's syndrome, etc; (3) Individuals with hypothalamic and/or pituitary dysfunction, such as hypogonadotropic hypogonadism; (4) Patients with combined pituitary (microadenoma) and ovarian cysts; (5) Combined with major diseases of cardiovascular, cerebrovascular, liver, kidney, and hematopoietic systems, as well as abnormal secretion function of adrenal and thyroid glands; (6) Patients with acute pelvic inflammatory disease and acute onset of chronic pelvic inflammatory disease; (7) Individuals with communication barriers, inability to accurately express skin burns, reflex pain, and other abnormal discomforts;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ovulate;Luteinizing hormone; | — |
Secondary
| Measure | Time frame |
|---|---|
| weight;waist circumference;Body fat percentage;Visceral Fat Area; | — |
Countries
China
Contacts
Public ContactMinshan Zhu; Dong Liang
Foshan First People's Hospital
Outcome results
None listed